Medtronic, Inc. (NYSE: MDT) today announced the U.S. Food & Drug Administration (FDA) approval of its AdaptiveStim™ with RestoreSensor™ neurostimulation system, the first and only chronic pain treatment that harnesses motion sensor technology found in smart phones and computer gaming systems to provide effective pain relief and convenience by automatically adapting stimulation levels to the needs of people with chronic back and/or leg pain.
Medtronic, Inc. announced today that a jury in the United States District Court of the Southern District of California in San Diego, found that NuVasive's CoRoent XL implants, MaXcess II and III retractors, and Helix and Helix mini anterior cervical plates infringe three patents owned by Medtronic.
The VeriChip Corporation has added Steven R. Foland to its board of directors. Lawson Software has expanded its human capital management leadership team with the appointment of Jennifer Langer...
